AccessPak for HIV PEP Expanded with Viracept Drug Interactions
Currently displaying 333 drugs known to have a major interaction with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir).
- 333 major drug interactions
- 317 moderate drug interactions
- 24 minor drug interactions
Major interactions with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir)
Note: Showing generic names only.
- abemaciclib
- acalabrutinib
- acyclovir
- adagrasib
- adefovir
- aldesleukin
- alfentanil
- alfuzosin
- alprazolam
- amikacin
- amikacin liposome
- amiodarone
- amphotericin b
- amphotericin b cholesteryl sulfate
- amphotericin b lipid complex
- amphotericin b liposomal
- apixaban
- astemizole
- atidarsagene autotemcel
- atogepant
- atorvastatin
- avacopan
- avanafil
- avapritinib
- axitinib
- bacitracin
- balsalazide
- berotralstat
- betibeglogene autotemcel
- betrixaban
- bosutinib
- botulism immune globulin
- brentuximab
- brexpiprazole
- brigatinib
- bromfenac
- bromocriptine
- budesonide
- butorphanol
- cabozantinib
- capivasertib
- capmatinib
- capreomycin
- carbamazepine
- carboplatin
- cariprazine
- caspofungin
- celecoxib
- ceritinib
- cerivastatin
- cidofovir
- cilostazol
- cisapride
- cisplatin
- clofarabine
- cobimetinib
- colchicine
- colistimethate
- conivaptan
- copanlisib
- crizotinib
- cyclophosphamide
- cyclosporine
- cytomegalovirus immune globulin
- daclatasvir
- daridorexant
- darifenacin
- dasatinib
- deferasirox
- deferoxamine
- deflazacort
- dexlansoprazole
- diatrizoate
- diclofenac
- didanosine
- diflunisal
- dihydroergotamine
- disopyramide
- docetaxel
- dronedarone
- drospirenone
- duvelisib
- edetate calcium disodium
- edetate disodium (edta)
- edoxaban
- elacestrant
- elagolix
- eletriptan
- eliglustat
- elivaldogene autotemcel
- encorafenib
- enfortumab vedotin
- entrectinib
- eplerenone
- erdafitinib
- ergonovine
- ergotamine
- erythromycin
- esomeprazole
- eszopiclone
- etidronate
- etodolac
- everolimus
- fedratinib
- fenoprofen
- fentanyl
- fesoterodine
- fexinidazole
- finerenone
- flibanserin
- flurbiprofen
- fluticasone
- fluticasone nasal
- foscarnet
- fosphenytoin
- fostamatinib
- futibatinib
- ibandronate
- ibrexafungerp
- ibrutinib
- ibuprofen
- ifosfamide
- iloperidone
- immune globulin intravenous
- immune globulin intravenous and subcutaneous
- indomethacin
- infigratinib
- inotersen
- iobenguane I 131
- iodamide
- iodipamide
- iodixanol
- iohexol
- iomeprol
- iopamidol
- iopromide
- iothalamate
- ioversol
- ioxaglate
- ioxilan
- irinotecan
- irinotecan liposomal
- isavuconazonium
- istradefylline
- ivabradine
- ivacaftor
- ivosidenib
- lamivudine
- lansoprazole
- lapatinib
- larotrectinib
- lefamulin
- leflunomide
- lemborexant
- levoketoconazole
- levomethadyl acetate
- levomilnacipran
- lifileucel
- lithium
- lomitapide
- lonafarnib
- loperamide
- lorlatinib
- lovastatin
- lovotibeglogene autotemcel
- lumateperone
- lurasidone
- lurbinectedin
- lutetium lu 177 dotatate
- lutetium lu 177 vipivotide tetraxetan
- macitentan
- maraviroc
- mavacamten
- meclofenamate
- mefenamic acid
- meloxicam
- mesalamine
- methotrexate
- methoxyflurane
- methylergonovine
- methylprednisolone
- methysergide maleate
- metrizamide
- midazolam
- midostaurin
- mifepristone
- mipomersen
- mirvetuximab soravtansine
- mitapivat
- mobocertinib
- modafinil
- morphine
- moxetumomab pasudotox
- olaparib
- oliceridine
- olsalazine
- omeprazole
- osilodrostat
- osimertinib
- oxaprozin
- oxcarbazepine
- oxycodone
- paclitaxel
- paclitaxel protein-bound
- pacritinib
- palbociclib
- palovarotene
- pamidronate
- panobinostat
- pantoprazole
- pazopanib
- pemigatinib
- penicillamine
- pentamidine
- pexidartinib
- phenobarbital
- phenylbutazone
- phenytoin
- pimavanserin
- pimozide
- piroxicam
- pirtobrutinib
- plazomicin
- polatuzumab vedotin
- polymyxin b
- ponatinib
- pralsetinib
- primidone
- rabeprazole
- ranolazine
- red yeast rice
- relugolix
- repotrectinib
- respiratory syncytial virus immune globulin
- rho (d) immune globulin
- ribociclib
- rifabutin
- rifampin
- rifapentine
- rimegepant
- riociguat
- ripretinib
- rivaroxaban
- rofecoxib
- rosuvastatin
- ruxolitinib
- salmeterol
- salsalate
- selpercatinib
- selumetinib
- sildenafil
- silodosin
- simeprevir
- simvastatin
- siponimod
- sirolimus
- sirolimus protein-bound
- solifenacin
- sonidegib
- sparsentan
- st. john's wort
- streptomycin
- streptozocin
- sulfasalazine
- sulindac
- suvorexant
- tacrolimus
- tamsulosin
- tazemetostat
- telavancin
- temsirolimus
- tepotinib
- terfenadine
- teriflunomide
- ticagrelor
- tipranavir
- tisotumab vedotin
- tobramycin
- tofacitinib
- tolmetin
- tolvaptan
- toremifene
- trabectedin
- triamcinolone
- triazolam
- valacyclovir
- valbenazine
- valdecoxib
- valganciclovir
- vancomycin
- venetoclax
- vilazodone
- vinblastine
- vincristine
- vincristine liposome
- vinorelbine
- voclosporin
- vonoprazan
- vorapaxar
- voxelotor
AccessPak for HIV PEP Expanded with Viracept alcohol/food interactions
There is 1 alcohol/food interaction with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir).
AccessPak for HIV PEP Expanded with Viracept disease interactions
There are 11 disease interactions with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir) which include:
- hepatitis B
- hepatotoxicity
- hemodialysis
- renal dysfunction
- liver disease
- PKU
- hemophilia
- hyperglycemia
- bone toxicity
- liver disease
- renal dysfunction
More about AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir)
- AccessPak for HIV PEP Expanded with Viracept consumer information
- Check interactions
- Compare alternatives
- Side effects
- Drug class: antiviral combinations
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.